May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Assessing Quality of Life in Glaucoma Patients Using the Glaucoma Quality of Life – 15 (GQL–15) Questionnaire
Author Affiliations & Notes
  • I. Goldberg
    Eye Associates, Sydney, Australia
    Sydney Eye Hospital, Sydney, Australia
  • C. Clement
    Eye Associates, Sydney, Australia
  • T.H. Chiang
    Health Outcomes Strategy and Research, Allergan, Inc., Irvine, CA
  • J.G. Walt
    Health Outcomes Strategy and Research, Allergan, Inc., Irvine, CA
  • A. Ravelo
    Health Outcomes Strategy and Research, Allergan, Inc., Irvine, CA
  • S. Graham
    Eye Associates, Sydney, Australia
    Save Sight Institute, University of Sydney, Sydney, Australia
  • P.R. Healey
    Eye Associates, Sydney, Australia
    Centre for Vision Research, Westmead Millennium Institute, Sydney, Australia
  • Footnotes
    Commercial Relationships  I. Goldberg, None; C. Clement, None; T.H. Chiang, Allergan, Inc. E; J.G. Walt, Allergan, Inc. E; A. Ravelo, Allergan, Inc. E; S. Graham, None; P.R. Healey, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 1902. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      I. Goldberg, C. Clement, T.H. Chiang, J.G. Walt, A. Ravelo, S. Graham, P.R. Healey; Assessing Quality of Life in Glaucoma Patients Using the Glaucoma Quality of Life – 15 (GQL–15) Questionnaire . Invest. Ophthalmol. Vis. Sci. 2005;46(13):1902.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Despite an insidious onset without symptoms, patients with open–angle glaucoma (OAG) may experience difficulty with daily activities from its early stage onwards. A new questionnaire, the GQL–15, has been specifically developed to assess quality of life (QoL) in glaucoma patients by measuring severity of visual disability for 5 key activity groups: (i) central and near vision, (ii) peripheral vision, (iii) dark adaptation and glare, (iv) personal care and (v) outdoor mobility. In this study we assessed QoL using the GQL–15 in a cohort of patients with OAG and correlated self–reported visual disability with objective measures of visual function. Methods: Patients with and without OAG attending an urban glaucoma practice and meeting the study’s exclusion criteria were enrolled from May to October 2004. All performed achromatic perimetry using a Humphrey Field Analyser (HFA) prior to completing the GQL–15. Information on glaucoma type, current treatment, visual acuity, HFA mean deviation (MD), HFA pattern standard deviation (PSD) and number of binocular points missed (≤ 20 degrees radius) were collected. Correlation coefficients were calculated using the Spearman’s correlation test. Results: 121 patients with OAG and 31 controls were enrolled. On a scale from 15 (no visual disability) to 75 (severe disability for all visual tasks), the mean GQL–15 summary score was 18.5 for controls and 30.5 for OAG. The GQL–15 summary score was significantly correlated with visual acuity (r=–0.39701, p<0.0001), MD (r=–0.47043, p<0.0001), disease severity (r=0.49278, p<0.0001), and number of binocular points missed (r=0.55821, p<0.0001). GQL–15 summary scores were significantly higher in patients with early (p<0.0019), moderate (p<0.0001) or advanced OAG (p<0.0001) compared to control. Conclusions: By using the GQL–15 questionnaire, we have demonstrated that patients with OAG report a decline in QoL compared to individuals without glaucoma. Reduced QoL in these patients correlates strongly with reduced VA, severity of visual field defects and presence of binocular field defects. Further analysis will reveal whether specific visual functions, such as glare and dark adaptation, are affected preferentially in early, moderate or advanced OAG.

Keywords: quality of life • visual fields • visual acuity 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.